Haemonetics Shares Drop 5.6% Amid Analyst Reactions and Trading Trends

Haemonetics Corporation (NYSE: HAE) experienced a notable decline of 5.6% in its share price during trading on Friday, hitting a low of $60.32 before last trading at $61.40. Approximately 451,712 shares exchanged hands, marking a 48% decrease from the average daily volume of 861,341 shares. The stock had previously closed at $65.02.

Market Reactions and Analyst Ratings

Various analysts have recently provided insights on Haemonetics’ stock performance. On December 11, 2023, CJS Securities upgraded the stock to a “strong-buy” rating. Meanwhile, Raymond James Financial maintained an “outperform” rating and set a price target of $90.00 in a report on November 14, 2023.

Conversely, Mizuho adjusted their target price downwards from $90.00 to $80.00, while still issuing an “outperform” rating. BTIG Research echoed a positive sentiment, reiterating a “buy” rating with a price target of $88.00. Weiss Ratings, however, opted for a more conservative stance, restating a “hold (c)” rating on December 29, 2023. Overall, one analyst rates the stock as a Strong Buy, six as Buy, four as Hold, and one as Sell, resulting in an average rating of “Moderate Buy” with a target price of $82.80, according to MarketBeat.com.

Financial Performance and Institutional Trading

Haemonetics boasts a debt-to-equity ratio of 1.08, a quick ratio of 1.03, and a current ratio of 1.64. The company’s market capitalization stands at $2.78 billion, with a price-to-earnings (P/E) ratio of 17.37 and a P/E growth (P/E/G) ratio of 1.37. The stock’s 50-day moving average price is $77.28, and its 200-day moving average price is $65.27.

In its most recent earnings report released on February 5, 2026, Haemonetics reported earnings per share (EPS) of $1.31, exceeding the consensus estimate of $1.27 by $0.04. The company achieved a return on equity of 27.22% and a net margin of 12.67%. Revenue for the quarter reached $338.97 million, surpassing analyst expectations of $331.90 million, though it represented a 2.7% decline year-over-year. Looking ahead, Haemonetics has set its fiscal year 2026 guidance at $4.90-$5.00 EPS, while analysts predict an average EPS of $4.55 for the current fiscal year.

Recent institutional trading activity has also impacted the stock. True Wealth Design LLC significantly increased its holdings in Haemonetics by 6,700% during the fourth quarter, now owning 340 shares valued at approximately $27,000. Other notable transactions include Leonteq Securities AG acquiring a new position valued at around $30,000 and EverSource Wealth Advisors LLC boosting its position by 2,640% in the second quarter, holding shares now valued at $31,000. As of now, institutional investors hold approximately 99.67% of Haemonetics’ stock.

Company Overview

Haemonetics Corporation is a global leader in blood management solutions, providing essential services that support the collection, processing, and transfusion of blood and its products. The company’s offerings aim to enhance patient safety and operational efficiency for blood centers, hospitals, and plasma collection facilities. Its diverse product range includes automated apheresis systems, surgical blood salvage devices, and pathogen reduction technologies, serving healthcare providers worldwide.

With the stock’s recent decline and mixed analyst ratings, investors may find themselves weighing the potential for recovery against current market trends.